Now I admit, I have not purchased this stock, just yet; but there are some aspects that I can't ignore.
#1. They have 250 million in accumulated losses. Now I'm no accountant, but I know that has significant value...tax-wise. I'm guessing that just might set a near term bottom of a 50 million market cap. Anybody purchasing this company for less than that, might be getting it for free.
#2. The burn for the last quarter is not nearly as bad as I thought it would be, so I assume that between Dec and March is equally not so bad.
So Alexio, my little Mescal buddy of late, suggests (and I can't believe I'm saying this) that APRI is not a bad risk currently. Since he believes that in the near term the stock cannot go below 1.25 (he actually used the word "impossible"), I'm going to have to declare that APRI is NOT the total frightening purchase that I thought it was a month ago. I truly believe that you can only lose half of your money if bought here. And that is more than I can say for most biotechs I follow.
Bicster, good to hear you again.
I have some questions too and for the results they have not answered the questions very good and have not said everything. We have got some answers and some are really not very clear to me.
It was a blunder with the French company and a takeover for a company in another country is always very difficult to understand what they are doing with the accountancy. Many companies have made the same mistakes and I should never buy another company in another country. They don't tell them everything of course. They have got the lessons, I hope so.
I think now we can come positive for Apri. My big question is : why Martin is going away when big things are coming? Perhaps his time is gone? Nevertheless when big things are on the way , why he don't be there at the great moment?
But let's be hopeful , our time is shorter and shorter to have the launch.
Bic,shooter my cat thinks they have enough cash on hand to last till Vitaros is launched and the royalties start rolling in. Once Europe kicks in, look out. Femprox to follow will with cash behind it will be a blockbuster.